Adjuvant pembrolizumab (Keytruda) for resected stage II melanoma significantly prolonged recurrence-free survival (RFS) compared with placebo, according to results from the…
Several studies at the 2021 virtual American Society of Clinical Oncology (ASCO) annual meeting were focused on the increased use of immune checkpoint…
Postoperative treatment of pancreatic cancer with nab-paclitaxel (Abraxane) and gemcitabine improved survival by more than 4 months as compared with gemcitabine alone, long-term…
Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with…
Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival compared with best supportive care after chemotherapy in patients with resected…
Currently, the combination of cyclin-dependent kinase (CDK)4/6 inhibitors with hormonal therapy -- aromatase inhibitors or fulvestrant -- is FDA-approved for first- and…
Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a…